Defining drug response for stratified medicine

Mike Lonergan; Stephen J. Senn; Christine McNamee; Ann K. Daly; Robert Sutton; Andrew Hattersley; Ewan Pearson; Munir Pirmohamed

doi:10.1016/j.drudis.2016.10.016

Defining drug response for stratified medicine

Mike Lonergan, Stephen J. Senn, Christine McNamee, Ann K. Daly, Robert Sutton, Andrew Hattersley, Ewan Pearson, Munir Pirmohamed^*

^*Corresponding author for this work

Competence Center for Methodology and Statistics

Research output: Contribution to journal › Review article › peer-review

19 Citations (Scopus)

Abstract

The premise for stratified medicine is that drug efficacy, drug safety, or both, vary between groups of patients, and biomarkers can be used to facilitate more targeted prescribing, with the aim of improving the benefit:risk ratio of treatment. However, many factors can contribute to the variability in response to drug treatment. Inadequate characterisation of the nature and degree of variability can lead to the identification of biomarkers that have limited utility in clinical settings. Here, we discuss the complexities associated with the investigation of variability in drug efficacy and drug safety, and how consideration of these issues a priori, together with standardisation of phenotypes, can increase both the efficiency of stratification procedures and identification of biomarkers with the potential for clinical impact.

Original language	English
Pages (from-to)	173-179
Number of pages	7
Journal	Drug Discovery Today
Volume	22
Issue number	1
DOIs	https://doi.org/10.1016/j.drudis.2016.10.016
Publication status	Published - 1 Jan 2017

Access to Document

10.1016/j.drudis.2016.10.016

Cite this

@article{a5603809633348ba9eb6902fe93f30da,

title = "Defining drug response for stratified medicine",

abstract = "The premise for stratified medicine is that drug efficacy, drug safety, or both, vary between groups of patients, and biomarkers can be used to facilitate more targeted prescribing, with the aim of improving the benefit:risk ratio of treatment. However, many factors can contribute to the variability in response to drug treatment. Inadequate characterisation of the nature and degree of variability can lead to the identification of biomarkers that have limited utility in clinical settings. Here, we discuss the complexities associated with the investigation of variability in drug efficacy and drug safety, and how consideration of these issues a priori, together with standardisation of phenotypes, can increase both the efficiency of stratification procedures and identification of biomarkers with the potential for clinical impact.",

author = "Mike Lonergan and Senn, {Stephen J.} and Christine McNamee and Daly, {Ann K.} and Robert Sutton and Andrew Hattersley and Ewan Pearson and Munir Pirmohamed",

note = "Publisher Copyright: {\textcopyright} 2016 Elsevier Ltd",

year = "2017",

month = jan,

day = "1",

doi = "10.1016/j.drudis.2016.10.016",

language = "English",

volume = "22",

pages = "173--179",

journal = "Drug Discovery Today",

issn = "1359-6446",

publisher = "Elsevier Ltd.",

number = "1",

}

TY - JOUR

T1 - Defining drug response for stratified medicine

AU - Lonergan, Mike

AU - Senn, Stephen J.

AU - McNamee, Christine

AU - Daly, Ann K.

AU - Sutton, Robert

AU - Hattersley, Andrew

AU - Pearson, Ewan

AU - Pirmohamed, Munir

PY - 2017/1/1

Y1 - 2017/1/1

N2 - The premise for stratified medicine is that drug efficacy, drug safety, or both, vary between groups of patients, and biomarkers can be used to facilitate more targeted prescribing, with the aim of improving the benefit:risk ratio of treatment. However, many factors can contribute to the variability in response to drug treatment. Inadequate characterisation of the nature and degree of variability can lead to the identification of biomarkers that have limited utility in clinical settings. Here, we discuss the complexities associated with the investigation of variability in drug efficacy and drug safety, and how consideration of these issues a priori, together with standardisation of phenotypes, can increase both the efficiency of stratification procedures and identification of biomarkers with the potential for clinical impact.

AB - The premise for stratified medicine is that drug efficacy, drug safety, or both, vary between groups of patients, and biomarkers can be used to facilitate more targeted prescribing, with the aim of improving the benefit:risk ratio of treatment. However, many factors can contribute to the variability in response to drug treatment. Inadequate characterisation of the nature and degree of variability can lead to the identification of biomarkers that have limited utility in clinical settings. Here, we discuss the complexities associated with the investigation of variability in drug efficacy and drug safety, and how consideration of these issues a priori, together with standardisation of phenotypes, can increase both the efficiency of stratification procedures and identification of biomarkers with the potential for clinical impact.

UR - http://www.scopus.com/inward/record.url?scp=85006379960&partnerID=8YFLogxK

U2 - 10.1016/j.drudis.2016.10.016

DO - 10.1016/j.drudis.2016.10.016

M3 - Review article

C2 - 27818254

AN - SCOPUS:85006379960

SN - 1359-6446

VL - 22

SP - 173

EP - 179

JO - Drug Discovery Today

JF - Drug Discovery Today

IS - 1

ER -

Defining drug response for stratified medicine

Abstract

Access to Document

Other files and links

Fingerprint

Cite this